ArsenalBio Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
127
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$325M
- Investors
-
25
ArsenalBio General Information
Description
Operator of a programmable cell therapy company intended to discover, develop, and commercialize curative immune cell therapies. The company offers a full-stack research and development engine that generates multifunctional T-cell medicines, enabled by the specific insertion of large synthetic deoxyribonucleic acid sequences, enabling clinicians with next-generation autologous T-cell therapies to defeat cancer.
Contact Information
Website
www.arsenalbio.comCorporate Office
- 329 Oyster Point Boulevard
- South San Francisco, CA 94080
- United States
Corporate Office
- 329 Oyster Point Boulevard
- South San Francisco, CA 94080
- United States
ArsenalBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series C) | 04-Sep-2024 | $325M | Completed | Clinical Trials - Phase 1 | ||
| 2. Early Stage VC (Series B) | 18-Nov-2022 | Completed | Clinical Trials - Phase 1 | |||
| 1. Early Stage VC (Series A) | 17-Oct-2019 | $85M | $85M | Completed | Clinical Trials - Phase 1 |
ArsenalBio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 18,967,560 | $0.000010 | $0.36 | $4.53 | $4.53 | 1x | $4.53 | 19.05% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
ArsenalBio Comparisons
Industry
Financing
Details
ArsenalBio Competitors (85)
One of ArsenalBio’s 85 competitors is Eureka Therapeutics, a Venture Capital-Backed company based in Emeryville, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Eureka Therapeutics | Venture Capital-Backed | Emeryville, CA | ||||
| Nkarta Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Arvinas | Formerly VC-backed | New Haven, CT | ||||
| Carisma Therapeutics | Formerly VC-backed | Philadelphia, PA |
ArsenalBio Patents
ArsenalBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260355246-A1 | Systems targeting psca and psma and methods of use thereof | Pending | 02-May-2025 | ||
| WO-2026232118-A1 | Systems targeting psca and psma and methods of use thereof | Pending | 02-May-2025 | ||
| WO-2026151965-A1 | Shrna targeting fas and tgfbrii genes | Pending | 10-Jan-2025 | ||
| WO-2026055342-A1 | Synthetic pathway activators | Pending | 04-Sep-2024 | ||
| AU-2025238278-A1 | Antigen binding proteins that bind tmprss4 and methods of use thereof | Pending | 20-Mar-2024 | C07K16/40 |
ArsenalBio Signals
ArsenalBio Investors (25)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARCH Venture Partners | Venture Capital | Minority | ||
| Luma Group | Accelerator/Incubator | Minority | ||
| Milky Way Investments Group | Venture Capital | Minority | ||
| NVentures | Corporate Venture Capital | Minority | ||
| Regeneron Ventures | Corporate Venture Capital | Minority |
ArsenalBio FAQs
-
When was ArsenalBio founded?
ArsenalBio was founded in 2018.
-
Where is ArsenalBio headquartered?
ArsenalBio is headquartered in South San Francisco, CA.
-
What is the size of ArsenalBio?
ArsenalBio has 127 total employees.
-
What industry is ArsenalBio in?
ArsenalBio’s primary industry is Drug Discovery.
-
Is ArsenalBio a private or public company?
ArsenalBio is a Private company.
-
What is the current valuation of ArsenalBio?
The current valuation of ArsenalBio is .
-
What is ArsenalBio’s current revenue?
The current revenue for ArsenalBio is .
-
How much funding has ArsenalBio raised over time?
ArsenalBio has raised $631M.
-
Who are ArsenalBio’s investors?
ARCH Venture Partners, Luma Group, Milky Way Investments Group, NVentures, and Regeneron Ventures are 5 of 25 investors who have invested in ArsenalBio.
-
Who are ArsenalBio’s competitors?
Eureka Therapeutics, Nkarta Therapeutics, Adaptimmune Therapeutics, Arvinas, and Carisma Therapeutics are some of the 85 competitors of ArsenalBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process